Pixantrone in relapsed or refractory aggressive non-Hodgkin’s lymphoma: a guide to its use
| Autor: | Gillian M. Keating, Katherine A. Lyseng-Williamson |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Bendamustine Oncology medicine.medical_specialty Vinorelbine 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine hemic and lymphatic diseases Internal medicine medicine Pharmacology (medical) Etoposide Mitoxantrone Pixantrone Ifosfamide business.industry medicine.disease Gemcitabine Non-Hodgkin's lymphoma Surgery 030104 developmental biology chemistry 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Drugs & Therapy Perspectives. 33:160-166 |
| ISSN: | 1179-1977 1172-0360 |
| DOI: | 10.1007/s40267-017-0391-0 |
| Popis: | Pixantrone (Pixuvri®) is an aza-anthracenedione with a novel mode of action. It is conditionally approved in the EU for use as monotherapy in adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma (NHL). In the pivotal, phase 3 PIX301 trial in patients with multiply relapsed or refractory aggressive NHL, the complete response plus unconfirmed complete response rate at the end of treatment (primary endpoint) was significantly higher with intravenous pixantrone monotherapy than with a single-agent comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone or gemcitabine). Pixantrone also demonstrated efficacy in the subgroup of patients with centrally confirmed aggressive B-cell NHL who were receiving third- or fourth-line therapy. Pixantrone was generally well tolerated in PIX301, with a manageable adverse event profile. In conclusion, pixantrone is a useful option in patients with multiply relapsed or refractory aggressive B-cell NHL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink